Clinical Trials on Glabella Line Severity

Total 5684 results

Medy-Tox

Completed

Efficacy and Safety Study of MT10109L in the Treatment of Glabella Line(Including a Preliminary Study to Evaluate Safety of MT10109L)

Glabella Line Severity

Korea, Republic of
Daewoong Pharmaceutical Co. LTD.

Completed

Efficacy and Safety of DWP450 Compared With Botox in Moderate to Severe Glabellar Line

Moderate to Severe Glabellar Line

Korea, Republic of
Daewoong Pharmaceutical Co. LTD.

Completed

Evaluate the Safety and Explore the Efficacy of DWP712 With Moderate to Severe Glabellar Lines

Glabellar Lines

Korea, Republic of
Allergan

Completed

A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Toxin-Naïve Adult Participants With Glabellar Lines

Glabellar Lines

United States, Canada
Medy-Tox

Completed

MT10109L in the Treatment of Glabellar Lines

Glabellar Lines

United States, Belgium, Russian Federation
CKD Bio Corporation

Completed

Safety and Efficacy of CKDB-501A in Subjects With Moderate-to-severe Glabellar Lines

Glabellar Lines

Korea, Republic of
Ipsen

Completed

Dysport in the Treatment of Glabellar Lines in Chinese Subjects

Glabellar Lines

China
Allergan

Completed

Safety and Efficacy of Two Types of Botulinum Toxin Type A For the Treatment of Glabellar Lines

Glabellar Lines

Germany
Huons Co., Ltd.

Completed

The Safety and Efficacy Study of HU-014 Versus Botox® in Subject With Moderate to Severe Glabellar Lines

Glabellar Lines

Korea, Republic of
GlaxoSmithKline

Completed

A Study Of BOTOX For The Treatment Of Glabellar Lines

Glabellar Lines

China
AbbVie

Recruiting

A Study to Evaluate AGN-151586 Intramuscular Injections in Adult Participants for Treatment of Glabellar Lines

Glabellar Lines

China, Taiwan
Hugel

Recruiting

Evaluate the Safety and Efficacy of HG102 as Compared to Botox® in Subject With Moderate to Severe Glabellar Lines

Glabellar Lines

Korea, Republic of
AbbVie

Completed

A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines

Glabellar Lines

United States, Canada, Germany, Hungary, Poland
Galderma R&D

Completed

Non-interventional Study, Long Term Treatment on Glabellar Lines With Dysport® in Subjects of Chinese Origin

Glabellar Lines

China
Allergan

Completed

A Study to the Assess the Change in Condition and Adverse Events of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines

Glabellar Lines

United States
Allergan

Completed

AGN-151586 Dose-Ranging Study for Treatment of Glabellar Lines

Glabellar Lines

United States
Huons Co., Ltd.

Completed

Phase 2 of HU-045 in Glabellar Lines

Glabellar Lines

Korea, Republic of
Ipsen

Completed

Efficacy and Safety of Botulinum Toxin Type A Haemagglutinin Complex Next Generation (BTX-A-HAC NG) in Glabellar Lines

Glabellar Lines

France, Germany, United Kingdom
BMI Korea

Completed

Treatment of Moderate to Severe Glabellar Lines (BMI2006) (BMI2006)

Glabellar Lines

Korea, Republic of
Ipsen

Completed

Patient and Physician's Satisfaction After a Long Term Treatment of Glabellar Lines With Dysport® (APPEAL)

Glabellar Lines

Australia, Brazil, Czechia, Kazakhstan, Lebanon, Russian Federation, Turkey, Ukraine
Galderma R&D

Completed

Assess Aesthetic Improvement With QM1114-DP in Subjects With Moderate to Severe Lateral Canthal Lines and Glabellar Lines

Glabellar Frown Lines | Canthal Lines

United States
Medy-Tox

Completed

MT10109L in the Long-term, Open-label Treatment of Glabellar Lines (GL) and Lateral Canthal Lines (LCL)

Lateral Canthal Lines | Glabellar Lines

United States, Russian Federation, Germany, Canada, Belgium, United Kingdom
Medy-Tox

Completed

MT10109L in the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar Lines

Lateral Canthal Lines | Glabellar Lines

United States, Germany, Canada
Medy-Tox

Completed

MT10109L in the Treatment of Glabellar Lines (GL) With or Without Concurrent Treatment of Lateral Canthal Lines (LCL)

Lateral Canthal Lines | Glabellar Lines

United States, Germany, Canada, United Kingdom
Pacira CryoTech, Inc., a wholly owned subsidiary...

Completed

Study Evaluating the Treatment of Forehead and/or Glabellar Lines With the CRYO-TOUCH III Device

Glabellar Frown Lines | Frown Lines

United States
Pacira CryoTech, Inc., a wholly owned subsidiary...

Completed

A Prospective Study Evaluating the Treatment of Forehead and/or Glabellar Lines With the Cryo-Touch IV Device

Glabellar Frown Lines | Frown Lines

United States
Jetema USA Inc.

Not yet recruiting

Clinical Trial to Evaluate the Safety and Efficacy of JTM201 to Treat Moderate or Severe Glabellar Lines

Glabellar Lines
Huons Biopharma

Not yet recruiting

To Evaluate HU-045 in the Treatment of Glabellar Lines(Phase III)

Glabellar Lines
AbbVie

Completed

A Study to Assess Adverse Events of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines

Glabellar Lines

United States, Puerto Rico
CKD Bio Corporation

Completed

Efficacy and Safety of CKDB-501A in Subjects With Moderate-to-severe Glabellar Lines in Phase 3 Trial

Glabellar Lines

Korea, Republic of
Allergan

Completed

A Study of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines

Glabellar Lines

United States
AbbVie

Completed

A Study to Evaluate Sequential Administration of AGN-151586 and OnabotulinumtoxinA (BOTOX) Injections in Adult Participants for Treatment of Glabellar Lines

Glabellar Lines

United States
CKD Bio Corporation

Completed

Safety and Efficacy of CKDB-501B in Subjects With Moderate-to-severe Glabellar Lines

Glabellar Lines

Korea, Republic of
Hugel

Completed

To Compare the Safety and Efficacy of "HG-102" With Botox® in the Improvement of Moderate to Severe Glabellar Lines.

Glabellar Lines

Korea, Republic of
Hugel
Sihuan Pharmaceutical Limited

Completed

Efficacy and Safety Assessment of Botulax® and BOTOX® for Improvement of Glabellar Lines.

Glabellar Lines

Korea, Republic of
Merz Pharmaceuticals GmbH

Completed

Safety and Efficacy of NT 201 (IncobotulinumtoxinA [Xeomin]) in the Treatment of Glabellar Frown Lines

Glabellar Lines

United States, Germany, Canada
Medy-Tox

Completed

Clinical Study to Evaluate the Efficacy and Safety of Neuronox and Botox With Moderate to Severe Glabellar Lines

Glabellar Lines
Revance Therapeutics, Inc.

Recruiting

Phase 2a Study of DaxibotulinumtoxinA-lanm for Injection in Dynamic Forehead Lines and Glabellar Lines

Glabellar Frown Lines

United States
ATGC Co., Ltd.

Recruiting

Study to Compare the Efficacy and Safety of ATGC-110 (Botulinum Toxin) With Xeomin® for the Treatment of Moderate to Severe Glabellar Frown Lines

Glabellar Frown Lines

Korea, Republic of
Galderma R&D

Completed

Assess Aesthetic Improvement and Onset of QM1114-DP in Subjects With Moderate to Severe Glabellar Lines

Glabellar Frown Lines

United States
Medy-Tox

Completed

Safety and Efficacy Study of Botulinum Toxin Type A to Treat Glabellar Lines

Glabellar Frown Lines

Australia
Galderma R&D

Completed

Safety and Efficacy Study of Botulinum Toxin for the Treatment of Glabellar Frown Lines

Glabellar Frown Lines

United States
Galderma R&D

Completed

Subject Satisfaction With AbobutulinumtoxinA Treatment (DREAM)

Glabellar Frown Lines

United States
Revance Therapeutics, Inc.

Completed

Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines

Glabellar Frown Lines

United States
Revance Therapeutics, Inc.

Completed

Safety of Single and Repeat Treatments of DaxibotulinumtoxinA for Injection for Treatment of Moderate to Severe Glabellar Lines

Glabellar Frown Lines

United States, Canada
Medytox Korea

Completed

Study to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Glabellar Lines

Glabellar Frown Lines

Korea, Republic of
Protox Inc.

Completed

The Safety and Efficacy Study of PROTOXIN in Subjects With Moderate to Severe Glabellar Lines

Glabellar Frown Lines

Korea, Republic of
Medy-Tox

Completed

Long-term Safety and Efficacy of MEDITOXIN® in Treatment Glabellar Lines

Glabellar Frown Lines

Korea, Republic of
Medy-Tox

Completed

The Efficacy and Safety of CUNOX® in Patients With Moderate to Severe Glabellar Lines

Glabellar Frown Lines

Russian Federation
Huons Co., Ltd.

Unknown

The Safety and Efficacy Study of Hutox Versus Botox® in Subject With Moderate to Severe Glabellar Lines

Glabellar Frown Lines

Korea, Republic of

3

Subscribe